Development trends for generation of single-chain antibody fragments

Immunopharmacology and Immunotoxicology

Volumn 36, Issue 5, 2014, Pages 297-308

  Farajnia, Safar ^a,b   Ahmadzadeh, Vahideh ^a   Tanomand, Asghar ^c   Veisi, Kamal ^b   Khosroshahi, Shiva Ahdi ^a   Rahbarnia, Leila ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Display methods; Improved stability; Single chain antibody fragments

Indexed keywords

A 300E; EPRATUZUMAB; G 28 5; MAB 57; MESSENGER RNA; MM 141; MONOCLONAL ANTIBODY; PH 1; RECOMBINANT ANTIBODY; SGN 10; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; IMMUNOGLOBULIN FRAGMENT; IMMUNOLOGIC FACTOR; PEPTIDE LIBRARY; RECOMBINANT PROTEIN;

CELL SURFACE DISPLAY; DRUG PROTEIN BINDING; FLOW CYTOMETRY; IMMUNOGLOBULIN VARIABLE REGION; IN VITRO STUDY; NONHUMAN; PHAGE DISPLAY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RIBOSOME; ANIMAL; CHEMISTRY; HUMAN; IMMUNOLOGY; PEPTIDE LIBRARY; VIRUS;

ANIMALS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOLOGIC FACTORS; PEPTIDE LIBRARY; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES; VIRUSES;

EID: 84925193468     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2014.945126     Document Type: Review

References (173)

1. Hudson PJ, Souriau C. Engineered antibodies. Nat Med 2003;9:129-134.
2. Pai JC, Sutherland JN, Maynard JA. Progress towards recombinant anti-infective antibodies. Recent Pat Antiinfect Drug Discov 2009;4:1-17.
3. Noguchi T, Kato T, Wang L. Intracellular tumor-associated antigens represent effective targets for passive immunotherapy. Cancer Res 2012;72:1672-1682.
4. Kim DJ, Chung JH, Ryu YS. Production and characterisation of a recombinant scFv reactive with human gastrointestinal carcinomas. Br J Cancer 2002;87:405-413.
5. Allison DE, Gourlay SG, Koren E, et al. Pharmacokinetics of rhuMAb CD18, a recombinant humanised monoclonal antibody fragment to CD18, in normal healthy human volunteers. BioDrugs 2002;16:63-70.
6. Bird RE, Hardman KD, Jacobson JW. Single-chain antigen-binding proteins. Science 1988;242:423-426.
7. Sharkey RM, Rossi EA, Chang CH, Goldenberg DM. Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies. Cancer Biother Radiopharm 2010;25:1-12.
8. Wang H, Liu X, He Y. Expression and purification of an anti-clenbuterol single chain Fv antibody in Escherichia coli. Protein Expr Purif 2010;72:26-31.
9. Brar HK, Bhattacharyya MK. Expression of a single-chain variable-fragment antibody against a Fusarium virguliforme toxin peptide enhances tolerance to sudden death syndrome in transgenic soybean plants. Mol Plant Microbe Interact 2012;25:817-824.
10. Huang D, Shusta EV. A yeast platform for the production of single-chain antibody-green fluorescent protein fusions. Appl Environ Microbiol 2006;72:7748-7759.
11. Geyer CR, McCafferty J, Dubel S, et al. Recombinant antibodies and in vitro selection technologies. Methods Mol Biol 2012;901:11-32.
12. Zahnd C, Spinelli S, Luginbuhl B. Directed in vitro evolution and crystallographic analysis of a peptide-binding single chain antibody fragment (scFv) with low picomolar affinity. J Biol Chem 2004;279:18870-18877.
13. Boder ET, Midelfort KS, Wittrup KD. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci USA 2000;97:10701-10705.
14. Jermutus L, Honegger A, Schwesinger F, et al. Tailoring in vitro evolution for protein affinity or stability. Proc Natl Acad Sci USA 2001;98:75-80.
15. Hawkins RE, Russell SJ, Winter G. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol 1992;226:889-896.
16. Hanes J, Pluckthun A. In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci USA 1997;94:4937-4942.
17. He M, Taussig MJ. Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites. Nucleic Acids Res 1997;25:5132-5134.
18. Yuan Q, Xia Y, Nian S, et al. Selection of single chain fragments against the phytopathogen Xanthomonas axonopodis pv. citri by ribosome display. Enzyme Microbial Technol 2007;41:383-389.
19. Chen W, Zhu Z, Xiao X, Dimitrov DS. Construction of a human antibody domain (VH) library. Methods Mol Biol 2009;525:81-99.
20. Josi D, Lim Y-P. Analytical and preparative methods for purification of antibodies. Methods for purification of antibodies. Food Technol Biotechnol 2001;39:215-226.
21. Criscitiello MF, Flajnik MF. Four primordial immunoglobulin light chain isotypes, including lambda and kappa, identified in the most primitive living jawed vertebrates. Eur J Immunol 2007;37:2683-2694.
22. Finlay WJ, Almagro JC. Natural and man-made V-gene repertoires for antibody discovery. Front Immunol 2012;3:342. doi: 10.3389/fimmu.2012.00342.
23. Darsley MJ, Rees AR. Nucleotide sequences of five anti-lysozyme monoclonal antibodies. EMBO J 1985;4:393-398.
24. Deng L, Luo M, Velikovsky A, Mariuzza RA. Structural insights into the evolution of the adaptive immune system. Annu Rev Biophys 2013;42:191-215.
25. Singhal S, Nie S, Wang MD. Nanotechnology applications in surgical oncology. Annu Rev Med 2010;61:359-373.
26. Nymalm Y, Kravchuk Z, Salminen T. Antiferritin VL homodimer binds human spleen ferritin with high specificity. J Struct Biol 2002;138:171-186.
27. Blenner MA, Banta S. Characterization of the 4D5Flu single-chain antibody with a stimulus-responsive elastin-like peptide linker: a potential reporter of peptide linker conformation. Protein Sci 2008;17:527-536.
28. Feng J, Xie Z, Guo N, Shen B. Design and assembly of anti-CD16 ScFv antibody with two different linker peptides. J Immunol Methods 2003;282:33-43.
29. Weatherill EE, Cain KL, Heywood SP, et al. Towards a universal disulphide stabilised single chain Fv format: importance of interchain disulphide bond location and vL-vH orientation. Protein Eng Des Sel 2012;25:321-329.
30. Gu X, Jia X, Feng J, et al. Molecular modeling and affinity determination of scFv antibody: proper linker peptide enhances its activity. Ann Biomed Eng 2010;38:537-549.
31. Zhu X, Wang D, Li S. Expression of a humanized single-chain variable fragment antibody targeting chronic myeloid leukemia cells in Escherichia coli and its characterization. Int J Mol Med 2012;29:939-945.
32. Shen Z, Mernaugh RL, Yan H, et al. Engineered recombinant single-chain fragment variable antibody for immunosensors. Anal Chem 2005;77:6834-6842.
33. Cardinale A, Filesi I, Mattei S, Biocca S. Intracellular targeting and functional analysis of single-chain Fv fragments in mammalian cells. Methods 2004;34:171-178.
34. Lobato MN, Rabbitts TH. Intracellular antibodies as specific reagents for functional ablation: future therapeutic molecules. Curr Mol Med 2004;4:519-528.
35. Hagemeyer CE, von Zur MC, von ED, Peter K. Single-chain antibodies as diagnostic tools and therapeutic agents. Thromb Haemost 2009;101:1012-1019.
36. Blanco-Toribio A, Sainz-Pastor N, Alvarez-Cienfuegos A. Generation and characterization of monospecific and bispecific hexavalent trimerbodies. MAbs 2013;5:70-79.
37. Pack P, Pluckthun A. Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. Biochemistry 1992;31:1579-1584.
38. Li SL, Liang SJ, Guo N, et al. Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth. Cancer Immunol Immunother 2000;49:243-252.
39. Hu S, Shively L, Raubitschek A, et al. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996;56:3055-3061.
40. Yao YD, Sun TM, Huang SY. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+breast cancer growth and metastasis. Sci Transl Med 2012;4:130ra48. doi: 10.1126/scitranslmed.3003601.
41. Tone Y, Kawahara M, Kawaguchi D, et al. Death signalobody: inducing conditional cell death in response to a specific antigen. Hum Gene Ther Methods 2013;24:141-150.
42. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010;10:301-316.
43. Sebastian M, Passlick B, Friccius-Quecke H. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study. Cancer Immunol Immunother 2007;56:1637-1644.
44. Sebastian M, Kuemmel A, Schmidt M, Schmittel A. Catumaxomab: a bispecific trifunctional antibody. Drugs Today 2009;45:589-597.
45. Topp MS, Gokbuget N, Zugmaier G. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012;120:5185-5187.
46. Bargou R, Leo E, Zugmaier G. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321:974-977.
47. Sebastian M, Kiewe P, Schuette W. Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x anti-CD3): results of a phase 1/2 study. J Immunother 2009;32:195-202.
48. Deyev SM, Lebedenko EN. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design. Bioessays 2008;30:904-918.
49. Deyev SM, Waibel R, Lebedenko EN, et al. Design of multivalent complexes using the barnase∗barstar module. Nat Biotechnol 2003;21:1486-1492.
50. Borsi L, Balza E, Carnemolla B, et al. Selective targeted delivery of TNFalpha to tumor blood vessels. Blood 2003;102:4384-4392.
51. Halin C, Gafner V, Villani ME, et al. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res 2003;63:3202-3210.
52. Rossi EA, Goldenberg DM, Cardillo TM, et al. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci USA 2006;103:6841-6846.
53. Yamamoto K, Trad A, Baumgart A. A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells. Biochem J 2012;445:135-144.
54. Rulker T, Voss L, Thullier P. Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo. PLoS One 2012;7:e37242.
55. Otz T, Grosse-Hovest L, Hofmann M, et al. A bispecific single-chain antibody that mediates target cell-restricted, supra-agonistic CD28 stimulation and killing of lymphoma cells. Leukemia 2009;23:71-77.
56. Xu L, Kohli N, Rennard R. Rapid optimization and prototyping for therapeutic antibody-like molecules. MAbs 2013;5:237-254.
57. Kuo SR, Wong L, Liu JS. Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells. Protein Eng Des Sel 2012;25:561-569.
58. Liu M, Wang X, Yin C, et al. Targeting TNF-alpha with a tetravalent mini-antibody TNF-TeAb. Biochem J 2007;406:237-246.
59. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 2003;44:1962-1969.
60. Glasgow JN, Mikheeva G, Krasnykh V, Curiel DT. A strategy for adenovirus vector targeting with a secreted single chain antibody. PLoS One 2009;4:e8355.
61. Schoonooghe S, Kaigorodov V, Zawisza M, et al. Efficient production of human bivalent and trivalent anti-MUC1 Fab-scFv antibodies in Pichia pastoris. BMC Biotechnol 2009;9:70.
62. Posey JA, Khazaeli MB, Bookman MA. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin Cancer Res 2002;8:3092-3099.
63. Du YJ, Lin ZM, Zhao YH. Stability of the recombinant anti-erbB2 scFv-Fc-interleukin2 fusion protein and its inhibition of HER2-overexpressing tumor cells. Int J Oncol 2013;42:507-516.
64. Zhong GS, Wu MN, Guo XF, et al. Antitumor activities of dFv-LDP-AE: an enediyne-energized fusion protein targeting tumor-associated antigen gelatinases. Oncol Rep 2012;28:1193-1199.
65. Skerra A, Pluckthun A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 1988;240:1038-1041.
66. Galeffi P, Lombardi A, Pietraforte I, et al. Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems. J Transl Med 2006;4:39. doi: 10.1186/1479-5876-4-39.
67. Ho M, Nagata S, Pastan I. Isolation of anti-CD22 Fv with high affinity by Fv display on human cells. Proc Natl Acad Sci USA 2006;103:9637-9642.
68. Choo AB, Dunn RD, Broady KW, Raison RL. Soluble expression of a functional recombinant cytolytic immunotoxin in insect cells. Protein Expr Purif 2002;24:338-347.
69. Hust M, Steinwand M, Al-Halabi L, et al. Improved microtitre plate production of single chain Fv fragments in Escherichia coli. N Biotechnol 2009;25:424-428.
70. Kraft M, Knupfer U, Wenderoth R, et al. A dual expression platform to optimize the soluble production of heterologous proteins in the periplasm of Escherichia coli. Appl Microbiol Biotechnol 2007;76:1413-1422.
71. Sonoda H, Kumada Y, Katsuda T, Yamaji H. Effects of cytoplasmic and periplasmic chaperones on secretory production of single-chain Fv antibody in Escherichia coli. J Biosci Bioeng 2011;111:465-470.
72. Wang R, Xiang S, Feng Y, et al. Engineering production of functional scFv antibody in E. coli by co-expressing the molecule chaperone Skp. Front Cell Infect Microbiol 2013;3:72. doi:10.3389/fcimb.2013.00072.
73. Rothe A, Hosse RJ, Power BE. In vitro display technologies reveal novel biopharmaceutics. FASEB J 2006;20:1599-1610.
74. Hust M, Dubel S. Mating antibody phage display with proteomics. Trends Biotechnol 2004;22:8-14.
75. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985;228:1315-1317.
76. Tesar D, Hotzel I. A dual host vector for Fab phage display and expression of native IgG in mammalian cells. Protein Eng Des Sel 2013;26:655-662.
77. Molek P, Strukelj B, Bratkovic T. Peptide phage display as a tool for drug discovery: targeting membrane receptors. Molecules 2011;16:857-887.
78. Du B, Qian M, Zhou Z. In vitro panning of a targeting peptide to hepatocarcinoma from a phage display peptide library. Biochem Biophys Res Commun 2006;342:956-962.
79. Hoogenboom HR, de Bruine AP, Hufton SE, et al. Antibody phage display technology and its applications. Immunotechnology 1998;4:1-20.
80. Ponsel D, Neugebauer J, Ladetzki-Baehs K, Tissot K. High affinity, developability and functional size: the holy grail of combinatorial antibody library generation. Molecules 2011;16:3675-3700.
81. Venet S, Ravn U, Buatois V, et al. Transferring the characteristics of naturally occurring and biased antibody repertoires to human antibody libraries by trapping CDRH3 sequences. PLoS One 2012;7:e43471.
82. Huse WD, Sastry L, Iverson SA, et al. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 1989;246:1275-1281.
83. Miethe S, Rasetti-Escargueil C, Liu Y, et al. Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library. MAbs 2014;6:446-459.
84. Hu ZQ, Liu JL, Li HP. Generation of a highly reactive chicken-derived single-chain variable fragment against Fusarium verticillioides by phage display. Int J Mol Sci 2012;13:7038-7056.
85. Marks JD, Hoogenboom HR, Bonnert TP, et al. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991;222:581-597.
86. Schwimmer LJ, Huang B, Giang H, et al. Discovery of diverse and functional antibodies from large human repertoire antibody libraries. J Immunol Methods 2013;391:60-71.
87. Loset GA, Lobersli I, Kavlie A, et al. Construction, evaluation and refinement of a large human antibody phage library based on the IgD and IgM variable gene repertoire. J Immunol Methods 2005;299:47-62.
88. Vaughan TJ, Williams AJ, Pritchard K, et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 1996;14:309-314.
89. Lloyd C, Lowe D, Edwards B, et al. Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of herapeutically relevant antigens. Protein Eng Des Sel 2009;22:159-168.
90. Sotelo P, Collazo N, Zuniga R. An efficient method for variable region assembly in the construction of scFv phage display libraries using independent strand amplification. MAbs 2012;4:542-550.
91. Soderlind E, Strandberg L, Jirholt P, et al. Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries. Nat Biotechnol 2000;18:852-856.
92. Soderlind E, Ohlin M, Carlsson R. Complementarity-determining region (CDR) implantation: a theme of recombination. Immunotechnology 1999;4:279-285.
93. Strachan G, McElhiney J, Drever M, et al. Rapid selection of anti-hapten antibodies isolated from synthetic and semi-synthetic antibody phage display libraries expressed in Escherichia coli. FEMS Microbiol Lett 2006;210:257-261.
94. Griffiths AD, Williams SC, Hartley O, et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J 1994;13:3245-3260.
95. Pini A, Viti F, Santucci A, et al. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998;273:21769-21776.
96. Villa A, Lovato V, Bujak E, et al. A novel synthetic naive human antibody library allows the isolation of antibodies against a new epitope of oncofetal fibronectin. MAbs 2011;3:264-272.
97. Braunagel M, Little M. Construction of a semisynthetic antibody library using trinucleotide oligos. Nucleic Acids Res 1997;25:4690-4691.
98. Knappik A, Ge L, Honegger A, et al. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J Mol Biol 2000;296:57-86.
99. Yu R, Wang S, Yu YZ, et al. Neutralizing antibodies of botulinum neurotoxin serotype A screened from a fully synthetic human antibody phage display library. J Biomol Screen 2009;14:991-998.
100. Hoogenboom HR. Overview of antibody phage-display technology and its applications. Methods Mol Biol 2002;178:1-37.
101. Griffiths AD, Williams SC, Hartley O. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J 1994;13:3245-3260.
102. Vaughan TJ, Williams AJ, Pritchard K, et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 1996;14:309-314.
103. Sheets MD, Amersdorfer P, Finnern R, et al. Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens. Proc Natl Acad Sci USA 1998;95:6157-6162.
104. Qiao Y, Zhou L, Wang Y. Screening for antibodies against intact cancer cells with a naive large phage antibody library. Int J Mol Med 2012;29:37-46.
105. Zhang GM, Chen YP, Guan YZ, et al. Modification and identification of a vector for making a large phage antibody library. Chin Med J 2007;120:2011-2016.
106. Pansri P, Jaruseranee N, Rangnoi K, et al. A compact phage display human scFv library for selection of antibodies to a wide variety of antigens. BMC Biotechnol 2009;9:6.
107. Chen W, Georgiou G. Cell-Surface display of heterologous proteins: from high-throughput screening to environmental applications. Biotechnol Bioeng 2002;79:496-503.
108. Wernerus H, Stahl S. Biotechnological applications for surface-engineered bacteria. Biotechnol Appl Biochem 2004;40:209-228.
109. Daugherty PS, Chen G, Olsen MJ, et al. Antibody affinity maturation using bacterial surface display. Protein Eng 1998;11:825-832.
110. Andreoni C, Goetsch L, Libon C, et al. Flow cytometric quantification of surface-displayed recombinant receptors on staphylococci. Biotechniques 1997;23:696-702,704.
111. Boder ET, Wittrup KD. Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 1997;15:553-557.
112. Wang XX, Cho YK, Shusta EV. Mining a yeast library for brain endothelial cell-binding antibodies. Nat Methods 2007;4:143-145.
113. Ferrara F, Naranjo LA, Kumar S, et al. Using phage and yeast display to select hundreds of monoclonal antibodies: application to antigen 85, a tuberculosis biomarker. PLoS One 2012;7:e49535.
114. Cho YK, Chen I, Wei X, et al. A yeast display immunoprecipitation method for efficient isolation and characterization of antigens. J Immunol Methods 2009;341:117-126.
115. Li Y, Siegel DL, Scholler N, Kaplan DE. Validation of glypican-3-specific scFv isolated from paired display/secretory yeast display library. BMC Biotechnol 2012;12:23.
116. Tillotson BJ, de Larrinoa IF, Skinner CA, et al. Antibody affinity maturation using yeast display with detergent-solubilized membrane proteins as antigen sources. Protein Eng Des Sel 2013;26:101-112.
117. Baek DS, Kim YS. Construction of a large synthetic human fab antibody library on yeast cell surface by optimized yeast mating. J Microbiol Biotechnol 2014;24:408-420.
118. Francisco JA, Campbell R, Iverson BL, Georgiou G. Production and fluorescence-activated cell sorting of Escherichia coli expressing a functional antibody fragment on the external surface. Proc Natl Acad Sci USA 1993;90:10444-10448.
119. Harvey BR, Georgiou G, Hayhurst A, et al. Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli-expressed libraries. Proc Natl Acad Sci USA 2004;101:9193-9198.
120. Ramesh B, Sendra VG, Cirino PC, Varadarajan N. Single-cell characterization of autotransporter-mediated Escherichia coli surface display of disulfide bond-containing proteins. J Biol Chem 2012;287:38580-38589.
121. Shimizu Y, Kuruma Y, Ying BW, et al. Cell-free translation systems for protein engineering. FEBS J 2006;273:4133-4140.
122. Sumida T, Yanagawa H, Doi N. In vitro selection of fab fragments by mRNA display and gene-linking emulsion PCR. J Nucleic Acids 2012;2012:371379.
123. Mattheakis LC, Bhatt RR, Dower WJ. An in vitro polysome display system for identifying ligands from very large peptide libraries. Proc Natl Acad Sci USA 1994;91:9022-9026.
124. He M, Taussig MJ. Antibody-ribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites. Nucleic Acids Res 1997;25:5132-5134.
125. Hanes J, Pluckthun A. In vitro selection and evolution of functional proteins by using ribosome display. Proc Natl Acad Sci USA 1997;94:4937-4942.
126. Luo Y, Xia Y. Selection of single-chain variable fragment antibodies against fenitrothion by ribosome display. Anal Biochem 2012;421:130-137.
127. Hanes J, Schaffitzel C, Knappik A, Pluckthun A. Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nat Biotechnol 2000;18:1287-1292.
128. Zhou L, Mao WP, Fen J, et al. Selection of scFvs specific for the HepG2 cell line using ribosome display. J Biosci 2009;34:221-226.
129. Blake DA, Chakrabarti P, Khosraviani M. Metal binding properties of a monoclonal antibody directed toward metal-chelate complexes. J Biol Chem 1996;271:27677-27685.
130. Shibui T, Kobayashi T, Kanatani K, et al. In vitro selection of scFv and its production: an application of mRNA display and wheat embryo cell-free and E. coli cell production system. Appl Microbiol Biotechnol 2009;84:725-732.
131. Miyamoto-Sato E, Ishizaka M, Horisawa K, et al. Cell-free cotranslation and selection using in vitro virus for high-throughput analysis of protein-protein interactions and complexes. Genome Res 2005;15:710-717.
132. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985;228:1315-1317.
133. Fukuda I, Kojoh K, Tabata N. In vitro evolution of single-chain antibodies using mRNA display. Nucleic Acids Res 2006;34:e127. doi: 10.1093/nar/gkl618.
134. Urban JH, Schneider RM, Compte M, et al. Selection of functional human antibodies from retroviral display libraries. Nucleic Acids Res 2005;33:e35. doi: 10.1093/nar/gni033.
135. Zhou C, Jacobsen FW, Cai L, et al. Development of a novel mammalian cell surface antibody display platform. MAbs 2010;2:508-518.
136. Ho M, Nagata S, Pastan I. Isolation of anti-CD22 Fv with high affinity by Fv display on human cells. Proc Natl Acad Sci USA 2006;103:9637-9642.
137. Bowers PM, Horlick RA, Neben TY, et al. Coupling mammalian cell surface display with somatic hypermutation for the discovery and maturation of human antibodies. Proc Natl Acad Sci USA 2011;108:20455-20460.
138. Alonso-Camino V, Sanchez-Martin D, Compte M, et al. Lymphocyte display: a novel antibody selection platform based on T cell activation. PLoS One 2009;4:e7174.
139. Alonso-Camino V, Sanchez-Martin D, Compte M, et al. CARbodies: human antibodies against cell surface tumor antigens selected from repertoires displayed on T cell chimeric antigen receptors. Mol Ther Nucleic Acids 2013;2:e93. doi: 10.1038/mtna.2013.19.
140. Xu X, Chen Y, Zhao Y, et al. Baculovirus superinfection: a probable restriction factor on the surface display of proteins for library screening. PLoS One 2013;8:e54631.
141. Kitidee K, Nangola S, Gonzalez G, et al. Baculovirus display of single chain antibody (scFv) using a novel signal peptide. BMC Biotechnol 2010;10:80.
142. Taube R, Zhu Q, Xu C, et al. Lentivirus display: stable expression of human antibodies on the surface of human cells and virus particles. PLoS One 2008;3:e3181.
143. Demarest SJ, Glaser SM. Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr Opin Drug Discov Devel 2008;11:675-687.
144. Poulin KL, Lanthier RM, Smith AC. Retargeting of adenovirus vectors through genetic fusion of a single-chain or single-domain antibody to capsid protein IX. J Virol 2010;84:10074-10086.
145. Worn A, Pluckthun A. Stability engineering of antibody single-chain Fv fragments. J Mol Bio 2001;305:989-1010.
146. Ho M, Kreitman RJ, Onda M, Pastan I. In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J Biol Chem 2005;280:607-617.
147. Fitzgerald J, Leonard P, Darcy E, et al. Light-chain shuffling from an antigen-biased phage pool allows 185-fold improvement of an anti-halofuginone single-chain variable fragment. Anal Biochem 2011;410:27-33.
148. Schier R, McCall A, Adams GP, et al. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol 1996;263:551-567.
149. Schier R, Bye J, Apell G, et al. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J Mol Biol 1996;255:28-43.
150. Qi Y, Wu C, Zhang S, et al. Selection of anti-sulfadimidine specific ScFvs from a hybridoma cell by eukaryotic ribosome display. PLoS One 2009;4:e6427.
151. Rajpal A, Beyaz N, Haber L, et al. A general method for greatly improving the affinity of antibodies by using combinatorial libraries. Proc Natl Acad Sci USA 2005;102:8466-8471.
152. Thakkar S, Nanaware-Kharade N, Celikel R, et al. Affinity improvement of a therapeutic antibody to methamphetamine and amphetamine through structure-based antibody engineering. Sci Rep 2014;4:3673. doi: 10.1038/srep03673.
153. Zhao JX, Yang L, Gu ZN, et al. Stabilization of the single-chain fragment variable by an interdomain disulfide bond and its effect on antibody affinity. Int J Mol Sci 2010;12:1-11.
154. Daugherty PS, Chen G, Olsen MJ, et al. Antibody affinity maturation using bacterial surface display. Protein Eng 1998;11:825-832.
155. Daugherty PS, Olsen MJ, Iverson BL, Georgiou G. Development of an optimized expression system for the screening of antibody libraries displayed on the Escherichia coli surface. Protein Eng 1999;12:613-621.
156. Duan Y, Gu TJ, Jiang CL. A novel disulfide-stabilized single-chain variable antibody fragment against rabies virus G protein with enhanced in vivo neutralizing potency. Mol Immunol 2012;51:188-196.
157. Trussel S, Dumelin C, Frey K, et al. New strategy for the extension of the serum half-life of antibody fragments. Bioconjug Chem 2009;20:2286-2292.
158. Andersen JT, Cameron J, Plumridge A, et al. Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics. J Biol Chem 2013;288:24277-24285.
159. Igawa T, Tsunoda H, Kuramochi T, et al. Engineering the variable region of therapeutic IgG antibodies. MAbs 2011;3:243-252.
160. McConnell AD, Spasojevich V, Macomber JL, et al. An integrated approach to extreme thermostabilization and affinity maturation of an antibody. Protein Eng Des Sel 2011;26:151-164.
161. Arndt MA, Krauss J, Schwarzenbacher R, et al. Generation of a highly stable, internalizing anti-CD22 single-chain Fv fragment for targeting non-Hodgkin's lymphoma. Int J Cancer 2003;107:822-829.
162. Miller BR, Demarest SJ, Lugovskoy A, et al. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel 2010;23:549-557.
163. Johdi NA, Harman R, Sanjuan I, et al. Production and binding analyses of a humanised scFv against a cryptic epitope on tumour-associated fibronectin. Protein Expr Purif 2013;88:157-163.
164. Fennell BJ, McDonnell B, Tam AS, et al. CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery. MAbs 2013;5:882-895.
165. Simeonov P, Berger-Hoffmann R, Hoffmann R, et al. Surface supercharged human enteropeptidase light chain shows improved solubility and refolding yield. Protein Eng Des Sel 2011;24:261-268.
166. Fink AL. Protein aggregation: folding aggregates, inclusion bodies and amyloid. Fold Des 1998;3:9-23.
167. Miklos AE, Kluwe C, Der BS. Structure-based design of supercharged, highly thermoresistant antibodies. Chem Biol 2012;19:449-455.
168. Chames P, Van RM, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 2009;157:220-233.
169. Schutte M, Thullier P, Pelat T. Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus. PLoS One 2009;4:e6625.
170. Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet 2009;373:1033-1040.
171. Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005;23:1105-1116.
172. Crepin R, Goenaga AL, Jullienne B. Development of human single-chain antibodies to the transferrin receptor that effectively antagonize the growth of leukemias and lymphomas. Cancer Res 2010;70:5497-5506.
173. Wiiger MT, Gehrken HB, Fodstad O, et al. A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth. Cancer Immunol Immunother 2010;59:1665-1674.